We have created a highly focused and productive research organization that has progressed a number of internal compounds into the clinic since our founding in 2002. Anacor has a growing pipeline, with an expanding clinical development portfolio focused on developing topical applications of our compounds to treat fungal, bacterial and inflammatory diseases. In addition, Anacor is developing systemic antiviral and antibacterial therapeutics under a research and development agreement with GSK.